ReviewSeminars in immunopathology2025
Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment.
Review in Seminars in immunopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Oral Zinc Supplementation in Acne Vulgaris and Hidradenitis Suppurativa: An Updated Comprehensive Review.Nutrients · 2026Review
- [Cutaneous presentation of digestive tract disorders and liver disease].Dermatologie (Heidelberg, Germany) · 2026Review
- Disproportionality analysis of pyoderma gangrenosum reporting to the FDA Adverse Event Reporting System in association with antirheumatic biologics.Clinical rheumatology · 2026Article
- Clinical Decision-Making and Multidisciplinary Management of Peristomal Pyoderma Gangrenosum in Stage IVB Rectal Cancer: A Case Report-Corticosteroid Response but Fatal Cancer Progression.Reports (MDPI) · 2026Article
- A rare case report of pyodermatitis vegetans linked with inflammatory bowel disease in juvenile population.Journal of medical case reports · 2026Article
- Pyoderma Gangrenosum with Pseudoepitheliomatous Hyperplasia Histopathologically Misdiagnosed as Squamous Cell Carcinoma: A Case Report and Brief Literature Review.Clinical, cosmetic and investigational dermatology · 2026Article
- Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor.Frontiers in immunology · 2026Article
- Recurrent Pyoderma Gangrenosum with Initial Onset in Early Pregnancy: A PARACELSUS-Supported Clinical Diagnosis in a Resource-Limited Setting in South-Western Uganda.International medical case reports journal · 2026Article
- Sweet's syndrome during anti-TNF therapy with successful rescue using a JAK inhibitor in refractory ulcerative colitis: a case report and literature review.Frontiers in immunology · 2026Review
- Achieving Steroid-Sparing Remission in Refractory Pyoderma Gangrenosum With an Integrative Meta-Therapeutic System Based on Traditionally Engineered Nanomercury Sulfide: A Case Series.Case reports in dermatological medicine · 2026Article
- Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report.Frontiers in medicine · 2026Article
- Case Report: Pyoderma gangrenosum masquerading as skin and soft tissue infection preceding myelodysplastic syndrome.Frontiers in medicine · 2026Article
- Probable pyoderma gangrenosum complicated with cutaneousFrontiers in medicine · 2026Article
- Development of Pyoderma Gangrenosum in a Patient with Acquired Reactive Perforating Collagenosis.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pyoderma gangrenosum (PG) is a rare inflammatory skin disease belonging to the group of neutrophilic dermatoses. The pathogenesis of PG involves a predisposing genetic background that facilitates a dysregulated innate and adaptive immune response, with an imbalance between pro-inflammatory and anti-inflammatory mediators, leading to neutrophil-driven inflammatory damage. Several immunosuppressants and immunomodulatory drugs are currently available for the treatment of PG, in combination with topical therapies, wound management and pain control strategies. Systemic corticosteroids and cyclosporine remain the first-line treatment options with the best evidence. However, in recent years, the rise of knowledge about different pathogenic mechanisms has led to a significant increase in studies attesting the efficacy and safety of biologic therapies including, among others, antagonists of tumour necrosis factor (TNF)-α and interleukin (IL)-23, becoming the drug of choice in specific clinical setting. Similarly, different small molecules such as JAK-STAT (Janus kinase/signal transducer and activator of transcription) inhibitors are showing promising results for the treatment of PG. We review established and emerging pathogenesis-driven treatments, also providing a therapeutic algorithm and informing future directions in the management of PG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.